IP Library Granted Patent US 10,676,500
Granted Patent B2
US 10,676,500 · App. 15/948,370 · Granted Jun 9, 2020

Process for preparation of sulfonyl carbamate bile acid derivatives

Inventors: Guoqiang Wang (Belmont, MA); Yong He (Lexington, MA); Brett Granger (Sudbury, MA); Xuechao Xing (Wilmington, MA); Yat Sun Or (Watertown, MA)
Assignee: Enanta Pharmaceuticals, Inc.
C07J41/005C07J41/0055C07J43/003C07J9/005C07J51/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,676,500
App. No.
15/948,370
Granted
Jun 9, 2020
Kind
B2
Abstract

The present invention relates to processes for preparing compounds of Formula (I) and compounds of Formula (II): These compounds are useful as FXR or TGR5 modulators. The present invention also relates to processes for the preparation of the compounds of Formula (III), Formula (IV), Formula (V), and Formula (VI), The present invention also relates to a process for the preparation of compounds (VII), (VIII) and (IX),

Claims (49)

1. A process for preparing a compound of Formula (II):

wherein

R 1 is selected from the group consisting of:

1) substituted or unsubstituted —C 1 -C 8 alkyl;

2) substituted or unsubstituted —C 2 -C 8 alkenyl;

3) substituted or unsubstituted —C 2 -C 8 alkynyl;

4) substituted or unsubstituted —C 3 -C 8 cycloalkyl;

5) substituted or unsubstituted aryl;

6) substituted or unsubstituted arylalkyl;

7) substituted or unsubstituted 3- to 12-membered heterocycloalkyl;

8) substituted or unsubstituted heteroaryl;

9) substituted or unsubstituted heteroarylalkyl; and

10) NR a R b , wherein, R a and R b are each independently selected from hydrogen, substituted or unsubstituted —C 1 -C 8 alkyl, substituted or unsubstituted —C 2 -C 8 alkenyl, substituted or unsubstituted —C 2 -C 8 alkynyl, substituted or unsubstituted —C 3 -C 8 cycloalkyl; alternatively R a and R b are taken together with the nitrogen atom to which they are attached to form a 3- to 12-membered hetercyclic ring;

said process comprising the steps of:

(1ai) reacting compound 1,

with a C 1 -C 6 -alkanol under acid catalysis to produce compound 2,

wherein R 6 is C 1 -C 6 -alkyl;

(1aii) reacting compound 2 with a strong base in the presence of a hydroxyl protecting agent to produce a compound of Formula 2a,

and reacting the compound of Formula 2a with a halogenating agent to produce compound 3,

wherein

PG 1 is a hydroxyl protecting group; and

R 2 is selected from Br, I, and C 1 ;

(1aiii) reacting compound 3 with an organic base to eliminate HR 2 and produce compound 4,

(1aiv) deprotecting compound 4 to produce compound 5,

(1av) reacting compound 5 with a hydroxyl protecting agent to produce compound 6:

(1avi) oxidatively cleaving and oxidizing compound 6 in the presence of a base to produce a compound of Formula (III):

(2bi) reacting the compound of Formula (III) with a C 1 -C 6 -alkanol under acid catalysis to produce compound 8,

(2bii) reacting compound 8 with a silylating agent in the presence of a base to produce compound 9:

wherein PG 3 is a silyl group;

(2biii) reacting compound 9 with acetaldehyde in the presence of a Lewis acid to produce compound 10:

(2biv) hydrogenating compound 10 to produce compound 11:

(2bv) reacting compound 11 with a base in a protic solvent or a mixture of a protic solvent and a non-protic solvent to produce compound 12:

2b(vi) reacting compound 12 with a hydroxyl protecting agent to produce the compound of Formula (V),

(3bi) reacting the compound of Formula (V) with a compound of the formula R 3 OC(O)Cl to produce compound 13:

wherein R 3 is an alkyl group; and

(3bii) reducing compound 13 to produce the compound of Formula (VI),

(4bi) reacting the compound of Formula (VI) with a compound of Formula 15E,

wherein R 4 is imidazol-1-yl, alkyl-O, aryl-O, Cl, or —CCl 3 , in the presence of an organic base, to produce compound 17,

and

(4bii) deprotecting the compound of Formula 17 to produce the compound of Formula (II).

2. The process of claim 1 , wherein R 1 is

3. The process of claim 1 , wherein step (4bii) is conducted in an aprotic solvent at a temperature from about 0° C. to about 80° C.

4. The process of claim 1 , wherein the compound of Formula 15E is selected from compounds 15B, 15C and 15D:

wherein R 5 is alkyl or aryl.

5. The process of claim 1 , wherein the compound of Formula 15E is selected from compounds 20B, 20C and 20D:

wherein R 5 is alkyl or aryl.

6. The process of claim 1 wherein PG is TBS.

7. The process of claim 1 wherein R 6 is methyl.

8. The process according to claim 1 wherein R 6 is methyl and PG 1 is TBS.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2018
From: WANG, GUOQIANG; HE, YONG; GRANGER, BRETT; XING, XUECHAO; OR, YAT SUN
To: ENANTA PHARMACEUTICALS, INC.
Reel/Frame 046250/0767 →
Continuity (2)
Provisional Application 62483044 · Apr 7, 2017
Related Publication 20180291058A1 · Oct 11, 2018
Cited By (1)
US 12,281,140